Oncology Drugs Market is Expected to Reach $111.9 Billion, Globally, by 2020. Read more at: https://www.alliedmarketresearch.com/oncology-cancer-drugs-market Augmentation in the prevalence and incidence rate of various cancers, growing popularity of biological and targeted modalities, along with the patent expiration of major cancer drugs are expected to drive the growth of global oncology drugs market. However, high initial capital investment in new drug development, long-term side effects associated with chemotherapy, and high cost of advanced therapies (targeted and immunotherapies) would limit the growth of the market. Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types. Amongst various biologics, drugs based on monoclonal antibodies (mAbs) have gained significant attention in recent years due to their high efficacy. Global cancer drugs market accounted for $78,238.9 million in 2015. The cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars.

1. Global
Oncology/Cancer
Drugs Market
Forecast
2013 - 2020
Published Date: 24 Feb 2015 No. of pages : 159

2.  Oncology Drugs Market is Expected to Reach $111.9 Billion, Globally, by 2020, registering a
CAGR of 7.1% from 2014 to 2020.
 Increase in adoption of combination therapies instead of traditional cytotoxic therapies is a
major factor that contributes to the market growth.
 The combinational therapies which include targeted therapy and immunotherapy (Biologic
therapy), is expected to witness ~10% surge in its market share collectively by 2020.
 Augmentation in the prevalence and incidence rate of various cancers, growing popularity of
biological and targeted modalities, along with the patent expiration of major cancer drugs
are expected to drive the growth of global oncology drugs market.
 However, high initial capital investment in new drug development, long-term side effects
associated with chemotherapy, and high cost of advanced therapies (targeted and
immunotherapies) would limit the growth of the market.
Oncology Drugs Market Scenario

3. Therapeutic Modalities
• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
• Others
Cancer Types
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Respiratory/Lung Cancer
• Skin Cancer
• Other Cancers
Oncology Drugs Market Key Segments

4.  The global oncology drugs market is experiencing a shift in therapeutic modalities i.e. from
traditional cytotoxic agents to newly develop targeted and immunotherapeutic modalities.
 Tumor cell specificity, an attribute of aforementioned modality, has reduced drug remission
rates and has rendered an enhanced rate of survival in cancer patients thus, complementing
the market growth.
 chemotherapeutic modalities would continue to be the leading therapeutic modality
segment owing to its higher adoption rate and economic pricing.
 Going forward, the demand for the chemotherapy modality might confront a negative
influence due to marginal efficacy and chronic side effects such as anemia.
 Amongst these different cancer types, blood cancer was the largest revenue generating
segment in 2015. The growth of blood cancer segment is majorly due to the high cost of the
drugs used to treat blood cancer.
Oncology Drugs Market is further bifurcated based on

5. Drivers
 Rising incidence and prevalence of various cancer types
 Growing importance of biological and targeted drug therapies
 Expiration of key patents and Biosimilars impact
 Acquisitions and collaborations bolt-on strategies driving the market growth
Restraints
 High cost of drug development and threat of failure
 Adverse effects of anti-cancer drug therapy
Oncology Drugs Market Drivers And Restraints

6. Key Benefits
 Immunotherapy/biological drugs segment expected to grow
at a double digit CAGR during the forecast period and would
grow at the fastest rate
 Blood cancer is the major revenue generating segment in the
global oncology drug application market however, lung cancer
segment is expected to grow fastest among all
 Currently, North America garners a major share in the
oncology drugs market, in terms of market size
 Asia Pacific oncology drug market is dominated by China and
Japan, together contributing to ~60% of the regional market
revenue in 2014

7. Oncology Drugs Market By Geography
North America, Europe, Asia Pacific, LAMEA

8. Key Players Operating in Oncology Drugs Market
1. Roche diagnostics
2. Novartis AG
3. Celgene Corporation
4. AstraZeneca
5. Johnson & Johnson
6. Merck & Co.
7. Eli Lilly & Co.
8. Amgen Inc.
9. Pfizer
10. GlaxoSmithKline

9. Follow Us On
Thank You!
For More Details
Visit us at
https://www.alliedmarketresearch.com/oncology-cancer-
drugs-market